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that contributes to insulin resistance and dysfunctional protein
metabolism in skeletal muscle, resulting in debilitating muscle atrophy.
The saturated fatty acid palmitate (PA) induces muscle insulin resistance
and promotes apoptosis and atrophic signaling pathways. In contrast,
omega-3 polyunsaturated fatty acids like docosahexaenoic acid (DHA)
improve insulin sensitivity and may attenuate activation of pathways that
lead to muscle atrophy. The purpose of this study was to examine the
effects of saturated and omega-3 fatty acids on atrophy-related signaling
pathways in skeletal muscle cells. Our hypothesis was that DHA prevents
the detrimental effects of PA. C2C12 myotubes were treated with 0.1mM
DHA and/or 0.5mM PA for 48 h. Insulin (100nM; 15 min) was added to cells
to activate signaling pathways. The expression of proteins involved in
atrophic and apoptotic signaling pathways was examined by Western
analysis. PA reduced myotube size and number. PA also reduced insulin-
stimulated Akt and Foxo3a phosphorylation plus induced caspase-3 and
actin-fragmentation. All of these responses were blocked by the addition of
DHA; DHA alone had minimal effects on these pathways. In conclusion,
these data suggest that DHA protects muscle cells from activation of
atrophic signaling pathways by high levels of saturated fatty acids.
Therefore, protein-energy wasting during CKD may be improved by DHA
supplements.Support: NIH DK007734
http://dx.doi.org/10.1016/j.krcp.2012.04.624301
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Muscle atrophy is prevalent in chronic kidney disease (CKD) patients.
MicroRNAs play a critical role in biological processes including muscle
atrophy. MicroRNA-23a (miR-23a) negatively regulates the expression of
two atrophy-related ubiquitin ligases, atrogin-1 and MuRF1; it is reduced
in muscle during atrophy. Although miR-23a expression was recently
shown to be positively regulated by NFATc3, the underlying mechanism of
miR-23a suppression during atrophy remains unknown. We previously
reported that the activity of calcineurin (Cn), the calcium-activated
phosphatase that regulates NFATc proteins, is decreased when insulin
signaling is decreased. Since CKD causes muscle atrophy, and
glucocorticoids are required for the response, we investigated how
dexamethasone (DEX) affects Cn activity, NFATc3 signaling, and miR-23a
expression. C2C12 or L6 myotubes were treated with 100 uM DEX to
induce atrophy. Within 1 h, Cn activity was reduced and less NFATc3 was
located in the nucleus. Further, miR-23a was also decreased within 30
minutes. After 48 h, expression of the NFATC3 target gene, MCIP1.4, and
miR-23a were decreased. Expression of atrogin-1 and MuRF1 were also
increased 48 h after DEX. Collectively, these ﬁndings indicate the Cn-NFAT
signaling pathway may play an important role in the regulation of atrogin-
1 and MuRF1 by suppressing miR23a during CKD and glucocorticoid-
related muscle atrophy. Support: NIH DK007656; AHA GRNT7660020
http://dx.doi.org/10.1016/j.krcp.2012.04.625302
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The Integrative Clinical Nutrition Dialysis Score is a new quantitative
method for identifying nutritional risk in hemodialysis patients. It is based
on biochemical measures and weight change taken as a part of the patient’s
monthly routine care and can be accomplished within a short time
following completion of laboratory results. The Scoring result is a number
between 0-100 given for each patient. A higher Score indicates a good
nutritional status, a lower Score represents malnutrition. The Score
identiﬁes also a monthly change in nutritional status, and patients who
should receive nutritional intervention. In 59 patients, Score results were
found to be signiﬁcantly correlated with nutrition evaluation by theSubjective Global Assessment taken within the same month. In 165
patients, baseline score emerged as a signiﬁcant inverse predictor of
mortality and hospitalization: each 1-unit increase in score reduced
mortality risk by 7.1%, and reduced hospitalization risk by 6.5%. A 1- unit
increase of slope of monthly scores reduced mortality risk by 23.6% and
reduced hospitalization risk by 20.1%. A threshold of Score greater or equal
to 75 reduced mortality by 64.2%. Patients were divided into four
categories based on baseline score (above/equal or below a threshold of 75)
and slope of monthly scores (smaller or larger/equal to 0). Worsening
nutrition status over time as indicated by both score and slope, signiﬁcantly
increased death hazard. Results conﬁrm that Integrative Clinical Nutrition
Dialysis Score (ICNDS) is a simple, useful prognostic tool to reﬂect
hemodialysis patients nutrition status, and nutrition deterioration at its
very commencement.
http://dx.doi.org/10.1016/j.krcp.2012.04.626303
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Peginesatide (P) is a synthetic, pegylated, peptide-based ESA approved
for treatment of anemia due to chronic kidney disease in adult patients
(pts) on dialysis. P demonstrated noninferiority to epoetin (E) in
maintenance of Hb levels in hemodialysis (HD) pts in two Phase
3 randomized, active-controlled, open-label trials (EMERALD 1,2). A large
dialysis organization (LDO) recently reported an ESA dose adjustment rate
of 12.1/pt-year (Bond et al, ISPOR 2012). This post hoc analysis evaluated
dosing practices for maintaining Hb with P vs E.
Pooled data from the two trials compared P (1x monthly; N¼1066) with
E (1-3x wkly; N¼542) in HD pts previously on stable doses of E. Hb was
measured during screening, at baseline and wkly (evaluation period, wks
29-36) or every 2 wks (all other periods). Dose adjustments were not to be
made more frequently than every 4 wks, unless required for safety
purposes. Dose adjustments (deﬁned as change 4720% from last dose)
were evaluated during the titration (wks 0-28), evaluation, and long-term
follow-up (LT, wks 36-52) periods. Dose postponements were deﬁned as
435d for P; for E, they were 44d, 6d, or 9d for TIW, BIW, and QW,
respectively.
Across the entire study period, P doses were adjusted 3 times less
frequently and held 8 times less than P (Table).P (per pt-year) E (per pt-year) E/P ratioTotal Dose Adjustments 3.5 10.3 2.9
Dose Increases 1.7 5.3 3.0
Dose Decreases 1.8 5.0 2.8
Dost Postponements 0.6 5.0 8.3Within each treatment arm, dose adjustment and postponement rates
(including corresponding E/P ratios) were similar across titration,
evaluation, and LT periods.
E dose adjustment rate was similar to that of real world practice in an
LDO. E doses were adjusted and held more frequently than P despite
similar protocol speciﬁcations for dose alteration and Hb maintenance.
http://dx.doi.org/10.1016/j.krcp.2012.04.627304
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Recent post hoc analyses of large randomized clinical trials have
suggested an association between high ESA dose and cardiovascular events
